Skip to main content
Premium Trial:

Request an Annual Quote

UCB, Imperial College Team Up to Identify Epilepsy Gene Regulators

NEW YORK (GenomeWeb News) – UCB today announced a two-year partnership with Imperial College London to identify master genetic regulators of brain networks that underlie epileptic activity.

The collaboration, UCB said, may result in the discovery of new drug targets and is the first time that cutting edge technologies, such as RNA sequencing and genome-wide approaches, will be applied to translational epilepsy research.

Up to 30 percent of epileptics do not respond to available treatments and continue to have uncontrollable seizures, Michael Johnson, an honorary reader in neurology at Imperial College London, and Enrico Petretto, senior lecturer in genomic medicine at the college, said.

"The aim of our partnership with UCB is to use state-of-the-art genomic approaches to identify causal molecular pathways for epilepsy and ultimately to identify and validate new drug targets to modify these pathways," they said in a statement.

Financial terms of the deal were not disclosed.

UCB is a Belgian biopharmaceutical company. It also said today that it is lending its support to the Quarriers Scottish Epilepsy Centre, which is slated to open next spring.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.